快速解离型CD19 CAR-T治疗成人复发难治B-ALL的持久缓解与低毒性
多中心I期ALLCAR19研究评估自体快速解离型CD19 CAR-T(AUTO1)治疗复发难治成人B-ALL,25例采集、24例制备、20例输注。未发生≥3级细胞因子释放综合征,85%在1个月达MRD阴性完全缓解,6和12个月无事件生存率分别为68.3%和48.3%,CAR-T持久存在。
要点
- AUTO1在复发难治成人B-ALL中安全性可控,无≥3级细胞因子释放综合征。
- 1个月MRD阴性完全缓解率达85%,6和12个月无事件生存率分别为68.3%和48.3%。
- CAR-T高水平扩增且持久存在,末次随访时20例中15例仍有B细胞缺乏。
核心结论
- AUTO1在复发难治成人B-ALL中安全性可控、缓解率高且持久性好,初步数据支持其作为独立治疗进一步开发。
研究设计与样本
- 多中心I期ALLCAR19研究(NCT02935257),纳入≥16岁复发难治B-ALL患者,主要终点为毒性和制备可行性。
主要发现
- 25例采集、24例制备、20例输注;中位年龄41.5岁,45%预处理时骨髓原始细胞≥50%。
- 无患者发生≥3级细胞因子释放综合征;3/20(15%)发生3级神经毒性,经激素治疗72小时内恢复至≤1级。
- 17/20(85%)在1个月达MRD阴性完全缓解,其中3/17在缓解期接受异基因造血干细胞移植。
- 6和12个月无事件生存率分别为68.3%(42.4%-84.4%)和48.3%(23.1%-69.7%)。
- 观察到高水平扩增(Cmax 127,152 copies/µg基因组DNA)和持久CAR-T存在,末次随访时15/20仍有B细胞缺乏。
临床怎么用
- AUTO1可为复发难治成人B-ALL提供高缓解率和低重度细胞因子释放综合征风险的治疗选择。
- 治疗后需监测神经毒性并及时使用激素处理,同时关注B细胞缺乏和低丙种球蛋白血症。
局限性
- I期研究样本量小(20例输注),结论需更大规模研究验证。
- 原文未报告低丙种球蛋白血症的具体发生率与持续时间数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prognosis for adult B-cell acute lymphoblastic leukemia (B-ALL) is poor, and there are currently no licensed CD19 chimeric antigen receptor (CAR) therapeutics. We developed a novel second-generation CD19-CAR (CAT19-41BB-Z) with a fast off rate, designed for more physiologic T-cell activation to reduce toxicity and improve engraftment. We describe the multicenter phase I ALLCAR19 (NCT02935257) study of autologous CAT19-41BB-Z CAR T cells (AUTO1) in relapsed or refractory (r/r) adult B-ALL. METHODS: Patients age ≥ 16 years with r/r B-ALL were eligible. Primary outcomes were toxicity and manufacturing feasibility. Secondary outcomes were depth of response at 1 and 3 months, persistence of CAR-T, incidence and duration of hypogammaglobulinemia and B-cell aplasia, and event-free survival and overall survival at 1 and 2 years. RESULTS: Twenty-five patients were leukapheresed, 24 products were manufactured, and 20 patients were infused with AUTO1. The median age was 41.5 years; 25% had prior blinatumomab, 50% prior inotuzumab ozogamicin, and 65% prior allogeneic stem-cell transplantation. At the time of preconditioning, 45% had ≥ 50% bone marrow blasts. No patients experienced ≥ grade 3 cytokine release syndrome; 3 of 20 (15%) experienced grade 3 neurotoxicity that resolved to ≤ grade 1 within 72 hours with steroids. Seventeen of 20 (85%) achieved minimal residual disease-negative complete response at month 1, and 3 of 17 underwent allogeneic stem-cell transplantation while in remission. The event-free survival at 6 and 12 months was 68.3% (42.4%-84.4%) and 48.3% (23.1%-69.7%), respectively. High-level expansion (Cmax 127,152 copies/µg genomic DNA) and durable CAR-T persistence were observed with B-cell aplasia ongoing in 15 of 20 patients at last follow-up. CONCLUSION: AUTO1 demonstrates a tolerable safety profile, high remission rates, and excellent persistence in r/r adult B-ALL. Preliminary data support further development of AUTO1 as a stand-alone treatment for r/r adult B-ALL.
引用
- Roddie C, Dias J, O'Reilly MA, et al. Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2021. PMID: 34464155. doi:10.1200/JCO.21.00917
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。